Kolexia
Kaminsky Marie Christine Oncologie médicale
Kaminsky Marie Christine
Oncologie médicale
Institut de cancérologie de Lorraine
Vandoeuvre-lès-Nancy, France
109 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Tumeurs de l'ovaire Carcinome épidermoïde Tumeurs de la tête et du cou Carcinome épidermoïde de la tête et du cou Carcinome épithélial de l'ovaire Récidive tumorale locale Métastase tumorale Tumeurs du côlon

Collaborateurs

Voir plus
Berton Dominique
Berton Dominique
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Sire Christian
Sire Christian
Hôpital du Scorff, Lorient, France
Lortholary Alain
Lortholary Alain
Alek Onco, Nantes, France
Joly Florence
Joly Florence
Hôpital Côte de Nacre, Caen, France

Industries

Voir plus
Merck-Serono
1 collaboration(s)
Dernière en 2021
MundiPharma
1 collaboration(s)
Dernière en 2020
ITEOS BELGIUM
1 collaboration(s)
Dernière en 2023
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
The Lancet. Healthy longevity   05 mars 2024
French national standard for the treatment of squamous cell carcinoma of upper aero-digestive tract - General principles of treatment.
Bulletin du cancer   27 février 2024
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecologic oncology   26 février 2024
National standard for the treatment of squamous cell carcinoma of upper aerodigestive tract.
Bulletin du cancer   08 février 2024
ELAN-UNFIT: Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation
Essai Clinique (Merck-Serono)   07 février 2024
940P Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
793P Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
CHIVA: Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
TAPAZ: A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Essai Clinique (Novartis)   05 septembre 2023
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
Gynecologic oncology   02 juin 2023